Abivax S.A. ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeNASDAQ

Market Capitalization7,718.97 mln

Float79.31 mln

Earnings Date12/14/2026

1-Year Forecast

163.58

Transformational upside

Relative Strength

37 / 100

Underperforming

Debt / Equity

0.00

Debt-free

Pre-Tax Margin

17,652%

Exceptional margin

ROE

-117

Deeply negative

ROA

-84.81

Deeply negative

Business Description

ABIVAX is a Paris-based drug development company founded in 2013, focused on creating treatments that work with the body's own immune system to manage long-term inflammatory conditions. Its most advanced medicine, obefazimod, is currently being tested in late-stage trials for ulcerative colitis and earlier-stage trials for Crohn's disease.

Key Fundamentals

EPS-6.08

ROE-117

ROIC-345

ROA-84.81

Interest Cover-9.37

EBITDA, mln-443

EV / EBITDA-16.85

EV / EBIT-16.79

Quote Details

Last 86.59

Change -2.47 (-2.77%)

Open 87.66

Volume 842,193

Turnover 72,925,488

Average Volume 1,041,346

Financial Ratios

Pre-Tax Profit Margin17,652

Leverage Ratio1.26

Current Ratio5.97

Price / Book17.40

Price / Tangible Book18.67

Debt / Equity0.00

Financial Strength

1-Year Target Price163.58

Short Ratio5.08

Short % of Float8.39

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	-1.61%	31 / 100
1 Month	-8.95%	31 / 100
2 Months	-32.35%	15 / 100
6 Months	-26.38%	23 / 100
1 Year	-12.48%	35 / 100